Prospective results for 5-year survival and toxicity of moderately hypofractionated radiotherapy with simultaneous integrated boost (SIB) in (very) high-risk prostate cancer.
Masson I, Larriviere L, Mahé MA, Azria D, Pommier P, Mesgouez-Nebout N, Giraud P, Peiffert D, Chauvet B, Dudouet P, Salem N, Noël G, Khalifa J, Latorzeff I, Guérin-Charbonnel C, Supiot S.
Masson I, et al. Among authors: salem n.
Clin Transl Radiat Oncol. 2023 Nov 17;44:100702. doi: 10.1016/j.ctro.2023.100702. eCollection 2024 Jan.
Clin Transl Radiat Oncol. 2023.
PMID: 38111609
Free PMC article.